Cargando…

A phase 2 randomized, double-blind, placebo-controlled study of tremelimumab for second and third line treatment in patients with unresectable pleural or peritoneal mesothelioma

Detalles Bibliográficos
Autores principales:	Krug, Lee, di Pietro, Alessandra, Narwal, Rajesh, Robbins, Paul, Fu, Dongyue, Shalabi, Aiman, Ibrahim, Ramy, Calabro, Luana, Kindler, Hedy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990330/ http://dx.doi.org/10.1186/2051-1426-1-S1-P132

Ejemplares similares

Exposure–Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status
por: Baverel, Paul, et al.
Publicado: (2019)

Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2022)

Tumor volume is an independent predictor of survival in patients with malignant pleural mesothelioma
por: Kircheva, Diana Y, et al.
Publicado: (2015)

Systemic Treatments for Mesothelioma: Standard and Novel
por: Kindler, Hedy Lee
Publicado: (2008)

Life Expectancy in Pleural and Peritoneal Mesothelioma
por: Shavelle, Robert, et al.
Publicado: (2017)

PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma
por: Kanteti, Rajani, et al.
Publicado: (2016)

Evidence to Date: Clinical Utility of Tremelimumab in the Treatment of Unresectable Hepatocellular Carcinoma
por: Ahmed, Zunirah, et al.
Publicado: (2023)

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
por: Song, Xuyang, et al.
Publicado: (2023)

Genomic landscape of pleural and peritoneal mesothelioma tumours
por: Hiltbrunner, Stefanie, et al.
Publicado: (2022)

Computed Tomography and Spirometry Can Predict Unresectability in Malignant Pleural Mesothelioma
por: Bellini, Alice, et al.
Publicado: (2021)

Tremelimumab
Publicado: (2012)

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
por: Forde, Patrick M., et al.
Publicado: (2021)

Secondary Malignant Peritoneal Mesothelioma of the Greater Omentum after Therapy for Primary Pleural Mesothelioma
por: Gutzeit, Andreas, et al.
Publicado: (2013)

Peritoneal mesothelioma metastasis to the tongue – Comparison with 8 pleural mesothelioma reports with tongue metastases
por: Vazquez, Melisa V., et al.
Publicado: (2015)

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
por: Hotta, Katsuyuki, et al.
Publicado: (2020)

Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy
por: White, Michael G., et al.
Publicado: (2020)

Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study
por: Calabrò, Luana, et al.
Publicado: (2021)

Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma
por: Kanteti, Rajani, et al.
Publicado: (2018)

MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma
por: Kanteti, Rajani, et al.
Publicado: (2014)

Malignant Pleural and Peritoneal Mesothelioma Consequential to Brief Indirect Asbestos Exposure
por: Singhal, Bharati, et al.
Publicado: (2014)

Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients
por: Stevenson, James P, et al.
Publicado: (2013)

EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma
por: Tan, Yi-Hung Carol, et al.
Publicado: (2019)

Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report
por: Pezzuto, Federica, et al.
Publicado: (2021)

Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM)
por: Hassan, Raffit, et al.
Publicado: (2015)

Tremelimumab: research and clinical development
por: Comin-Anduix, Begoña, et al.
Publicado: (2016)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Bilateral Pleural Mesothelioma In Situ and Peritoneal Mesothelioma In Situ Associated With BAP1 Germline Mutation: A Case Report
por: MacLean, Alyssa, et al.
Publicado: (2022)

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study
por: Nakano, Takashi, et al.
Publicado: (2020)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
por: Ye, Zhuo-miao, et al.
Publicado: (2022)

Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study
por: van Kooten, Job P, et al.
Publicado: (2022)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers
por: Sorino, Claudio, et al.
Publicado: (2023)

Peritoneal mesothelioma.
por: Kealey, W. D., et al.
Publicado: (1993)

Peritoneal mesothelioma.
por: Churg, J
Publicado: (1974)

Peritoneal mesothelioma
por: Greenbaum, Alissa, et al.
Publicado: (2020)

Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT
por: Kitajima, Kazuhiro, et al.
Publicado: (2021)

Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma
por: Yang, Liu, et al.
Publicado: (2022)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Pleural mesothelioma – case report
por: Klawiter, Anna, et al.
Publicado: (2010)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2jj0ga4rj973vgnd2jfgivfnqf